OUTLOOK THERAPEUTICS INC (OTLK)

NASDAQ
1.160
-0.040(-3.33%)
After Hours
1.200
+0.040(+3.448%)
- Real-time Data
  • Volume:
    410,775
  • Day's Range:
    1.150 - 1.190
  • 52 wk Range:
    0.684 - 2.865

OTLK Overview

Prev. Close
1.2
Day's Range
1.15-1.19
Revenue
-
Open
1.17
52 wk Range
0.684-2.865
EPS
-0.327
Volume
410,775
Market Cap
262.33M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
897,695
P/E Ratio
-3.65
Beta
0.877
1-Year Change
-46.05%
Shares Outstanding
226,144,634
Next Earnings Date
Dec 21, 2022
What is your sentiment on OUTLOOK THERAPEUTICS?
or
Market is currently closed. Voting is open during market hours.

OUTLOOK THERAPEUTICS INC News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

OUTLOOK THERAPEUTICS INC Analysis

OUTLOOK THERAPEUTICS INC Company Profile

OUTLOOK THERAPEUTICS INC Company Profile

Employees
9

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellSellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • Outlook Therapeutics Expands Commercial Team with Appointment of Senior Vice President of Commercial OperationsJoel Prieve brings nearly 20 years of commercial operations expertise and proven track record in sales and account managementISELIN, N.J., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced the appointment of Joel Prieve as Senior Vice President, Commercial Operations.“Outlook Therapeutics is thrilled to welcome Joel to our executive leadership team. We believe his background and expertise in commercialization and specialty biopharmaceutical distribution will be invaluable as we continue advancing our pre-launch commercial planning in anticipation of potential approval for ONS-5010 ophthalmic bevacizumab,” stated Jeff Evanson, Chief Commercial Officer of Outlook Therapeutics.Mr. Prieve has nearly twenty years of experience in commercial operations, most recently in the Xcenda division of AmerisourceBergen as Vice President of Business Development and previously in the IPN Solutions division. Over the course of his career, he has amassed valuable leadership experience in sales management and national account management across oncology and specialty biopharmaceutical markets. His expertise in Group Purchasing Organization (GPO) contracting for retina/ophthalmology markets and his proven track record of successful partnerships for new product launches will be key for Outlook Therapeutics’ advancement of ONS-5010 / LYTENAVA ™ (bevacizumab-vikg) towards potential commercialization.In his new role as SVP of Commercial Operations, Mr. Prieve will report to Jeff Evanson, Chief Commercial Officer of Outlook Therapeutics, and oversee all aspects of distribution, third-party logistics, HUB services and field resources to deliver an industry-leading customer experience.Mr. Prieve added, “I am delighted to join Outlook Therapeutics at such an important stage of its development. I look forward to working with Jeff and the rest of the team on the potential commercial launch of ONS-5010.” Outlook Therapeutics expects to submit a Biologics License Application (BLA) for ONS-5010 ophthalmic bevacizumab with the U.S. Food and Drug Administration (FDA) during the first quarter of 2022. In anticipation of potential FDA marketing approval in late 2022 or early 2023, Outlook Therapeutics’ commercial launch planning includes manufacturing with drug substance manufacturer FUJIFILM Diosynth Biotechnologies and best-in-class drug product manufacturer Aji Biopharma Services, distribution, sales force planning, physician and payor advisory board outreach, key opinion leader support and payor community engagement.To bring ONS-5010 to market in a way that benefits all stakeholders – patients, clinicians and payors – Outlook Therapeutics is in collaborative discussions with payors and the retina community. Outlook Therapeutics is also developing registration documents on a parallel path for approvals in Europe and expects to submit them in the fourth quarter of 2022. Outlook Therapeutics continues to explore potential strategic commercialization partners, such as Syntone Biopharma JV in China. Outlook Therapeutics expects ONS-5010, if approved, to be a safe and cost-effective choice for patients, clinicians and payors worldwide for retinal indications.
    0
    • ONS-5010. Hay incongruencias en fechas de aprobacion en las diferentes plataformas de consulta. Alguien puede aclarar (2021 o 2022?)
      1
      • Outlook Therapeutics (NASDAQ:OTLK) shareholder returns have been splendid, earning 198% in 1 year
        0
        • OTLK Price Targets:8,00 : Brookline Capital Markets, Following Clinical Business Update8,00/7,00/6,00 : BARCHART8,00/6,67/6,00 : YAHOO FINANCE (BUY) ; BARRONS (BUY) ; WEBULL (BUY) ; WSJ (BUY) ; STOCK NEWS (BUY) ; MARKET SCREENER (BUY) ; NASDAQ [STRONG BUY]8,00/6,00/6,00 : CNN BUSINESS (BUY) ; MARKET WATCH (BUY)7,00 ; ZACKS6,00 ; TIPRANKS (Moderate Buy) ; H C WAINWRIGHT ; MARKETBEAT [BUY]
          0
          • As expected..... buying pressure began last friday and continues .... Institutions have taken positions and built a base. We are in a Uptrend, Last "6 days" of OTLK continuous in a Uptrend.
            0
            • I closed yestrday my position on OTLK but very interested to join again, what are you targets?
              0
              • This is going to 8 soon
                0
                • Can you explain Why ? please
                  0
                • U need to do your research
                  0
                • Deepak Kalwani i did mine and want to know if my research is on right track.
                  0
              • Told you this was a garbage pump and dump stock
                4
                • Dump or HOLD ??
                  1
                  • Hold
                    0
                • flatline
                  1